A one-day meeting on Therapeutics and Antimicrobial Resistance (AMR) brings together researchers from industry and academia, clinicians, policymakers and early career scientists to explore new perspectives, expand horizons and foster long term collaborations.

TOPICS COVERED

• The morning will feature invited talks from leaders from the biotechnology industry, regulators, and government agencies, alongside a panel discussion on future directions in AMR therapeutics.
• The afternoon will be highly interactive, with structured networking sessions including a World Antimicrobial Awareness Week (WAAW) “sandpit” activity to generate creative ideas, promote networking and build awareness of and influence policy on the growing threat of AMR.
• The meeting aims to strengthen cross-disciplinary connections, highlight opportunities for impact, and catalyse new initiatives in therapeutics research, outreach and practice to minimise the effects of AMR as a public health threat.

WHO SHOULD ATTEND?

Researchers from industry and academia, clinicians, policymakers and early career scientists with an interest in AMR and therapeutics.

SPEAKERS

• Dr Colin Brown (UK Health Security Agency)

Dr Colin Brown is an Infectious Disease & Medical Microbiology clinician working at UK Health Security Agency on a portfolio of clinical and emerging infection, healthcare associated infection (HCAI), antimicrobial resistance (AMR) and global health. His time is currently split between treating patients with clinical infections (including high consequence infectious disease) at the Royal Free Hospital in London, and leading on domestic infection policy on AMR & HCAI as Deputy Director of the Epidemic & Emerging Infections and Head of the AMR & HCAI Division. He is co-Director of the WHO Collaborating Centre for Reference & Research on AMR & HCAI at UKHSA, and is UKHSA Lead for the University of Oxford NIHR Health Protection Research Unit in HCAI & AMR.

• Dr Carmen Coxon (Medicines & Healthcare products Regulatory Agency)

Dr Carmen Coxon worked in academia for 15 years, specialising in drug discovery and drug repurposing in the area haemostasis and cancer, before joining the MHRA in 2017 as a research fellow. At the MHRA, Dr Coxon worked on the development of reference materials to standardise clinical tests used in the diagnosis and monitoring of antidrug antibodies in haemophilia A, before taking a secondment as a digital product manager during the COVID pandemic. She rejoined the Science Campus in 2023 to join ongoing efforts supporting research and innovation in the antimicrobial resistance space, going on to secure a 3-year grant from the Global Antimicrobial Resistance Innovation Fund (GAMRIF) to support R&I across One Health and with a lower- and middle-income country focus.

• Dr Peter Jackson (BEAM Alliance & Infex Therapeutics)

Dr Peter Jackson is an experienced UK-based serial entrepreneur in the life sciences sector. Over the past 15 years, he has created seven new companies, targeting novel therapeutics across infection, oncology and immunology, as well as in agrochemicals and life sciences services. Dr Jackson has over 25 years’ experience in the sector, previously holding senior roles as commercial director and then VP of Avecia’s Pharmaceutical Products business unit, following senior roles at Zeneca and ICI. Dr Jackson is on the Project Advisory Group for NHS England/NICE on the new UK antibiotic reimbursement trial and is a member of a UKRI/BBSRC panel reviewing academic AMR investments and AMR strategy. He is a special advisor on AMR/pandemic preparedness to the Milken Institute. Dr Jackson has recently joined the board of the BEAM Alliance, a network of European AMR biotech companies lobbying for the implementation of AMR drug reimbursement reforms in the EU.